Chronic Hepatitis Clinical Trial
— WRITEOfficial title:
RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE)
Verified date | March 2022 |
Source | Casa Sollievo della Sofferenza IRCCS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
WRITE study aim at identifying the effectiveness of an innovative individualized schedule of treatment as compared to standard regimen in patients with chronic HCV genotype 2 and 3.
Status | Completed |
Enrollment | 1150 |
Est. completion date | November 30, 2019 |
Est. primary completion date | November 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Patients with chronic hepatitis C virus (HCV) infection (both HCVAb and HCV RNA positive) - Patients with HCV genotype 2 or 3 - Age 18-70 years - Naïve patients or previously treated only with standard interferon monotherapy - Female patients of childbearing age who agree to avoid pregnancy during the period of treatment and 24 weeks after the end of treatment Exclusion Criteria: - Previous treatment with ribavirin - Cirrhosis (CHILD PUGH B and C) - Evidence of Hepatocellular carcinoma - Pregnancy - Retinopathy class I or II - Alcohol consumption > 40 gr/day - Chronic cardiac or respiratory diseases - HIV or HBsAg or HDV positivity - Hemoglobin < 8.5 gr/dL - WBC < 3.500/mm3 - PLT < 80.000/mm3 |
Country | Name | City | State |
---|---|---|---|
Italy | Infectious Diseases Unit | Avellino | |
Italy | Clinical Medicine Unit "Mater Dei" | Bari | |
Italy | Università di Bari | Bari | |
Italy | Medicine Unit | Barletta | |
Italy | Infectious Diseases Unit "V. Emanuele" | Bisceglie | |
Italy | Medicine Unit | Canosa di Puglia | |
Italy | Hepatology Unit | Casarano | |
Italy | IRCCS "De Bellis" | Castellana | |
Italy | Hepatology Unit | Catania | |
Italy | Infectious Diseases Unit | Catania | |
Italy | Gastroenterology Unit | Como | |
Italy | Gastroenterology Unit Arcispedale "S. Anna" | Ferrara | |
Italy | Gastroenterology Unit | Firenze | |
Italy | Internal Medicine University of Firenze | Firenze | |
Italy | Gastroenterology Unit | Foggia | |
Italy | Infectious Diseases | Foggia | |
Italy | Gastroenterology Unit | Galatina | |
Italy | Infectious Diseases | Lucca | |
Italy | Gastroenterology Unit | Mottola | |
Italy | Gastroenterology Unit "Cardarelli" | Napoli | |
Italy | USL Napoli 1 | Napoli | |
Italy | Hospital "V. Cervello" | Palermo | |
Italy | Medical Clinic University of Palermo | Palermo | |
Italy | Infectious Diseases Unit IRCCS "San Matteo" | Pavia | |
Italy | Campus Biomedico University | Roma | |
Italy | Hepatology Unit "S. Pertini" | Roma | |
Italy | Hepatology Unit "san Camillo" | Roma | |
Italy | Ospedale "Villa Betania" | Roma | |
Italy | IRCCS "L. Spallanzani" | Rome | |
Italy | IRCCS "Casa Sollievo della Sofferenza" | San Giovanni Rotondo | |
Italy | Infectious Diseases Unit Ospedale Civile | Sassari | |
Italy | Medicine Unit | Sassari | |
Italy | Infectious Diseases | Siracusa | |
Italy | SS. Annunziata | Taranto | |
Italy | Medicine Unit | Venosa |
Lead Sponsor | Collaborator |
---|---|
Casa Sollievo della Sofferenza IRCCS | Arcispedale S. Anna, Ferrara, Azienda Ospedaliera V. Cervello, Azienda Ospedaliera, Lucca, Azienda Ospedaliera, Siracusa, Azienda Ospedaliero Universitaria di Sassari, Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliero-Universitaria, Catania, Campus Bio-Medico University, Cardarelli Hospital, Casa di Cura Mater Dei, IRCCS De Bellis, Castellana, IRCCS L. Spallanzani, IRCCS Policlinico S. Matteo, Ospedale Civile Spirito Santo, Ospedale Civile Vittorio Emanuele II, Bisceglie, Ospedale di Canosa di Puglia, Ospedale di Mottola, Ospedale di Venosa, Ospedale Francesco Ferrari, Ospedale Monsignor R. Dimiccoli, Barletta, Ospedale San Giuseppe Moscati, Avellino, Ospedale Sandro Pertini, Roma, Ospedale Santa Caterina Novella, Galatina, Ospedale SS. Annunziata, Taranto, Ospedale Valduce, Como, Ospedali Riuniti di Foggia, San Camillo Hospital, Rome, University of Bari, University of Florence, University of Palermo, USL Napoli 1 |
Italy,
Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404. doi: 10.1111/j.1365-2036.2008.03763.x. Epub 2008 Jun 11. Review. — View Citation
Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Aliment Pharmacol Ther. 2010 Jun;31(12):1346-53. doi: 10.1111/j.1365-2036.2010.04290.x. Epub 2010 Mar 8. — View Citation
Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009 Feb;49(2):358-63. doi: 10.1002/hep.22679. — View Citation
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005 Jun 23;352(25):2609-17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sustained virological Response (SVR) | The primary measure of efficacy will be HCV RNA not detectable in serum samples 24 weeks after the end of therapy (SVR). | 6 months after the end of treatment | |
Secondary | Rapid virological response (RVR) | proportion of patients with undetectable HCV RNA 4 weeks after the start of treatment | On treatment week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01833611 -
Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
|
Phase 4 | |
Completed |
NCT00771446 -
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03731923 -
Abbreviated MRI for HCC Surveillance
|
N/A | |
Recruiting |
NCT03013556 -
Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
|
Phase 4 | |
Recruiting |
NCT05181826 -
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
|
||
Active, not recruiting |
NCT02143180 -
Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study
|
N/A | |
Completed |
NCT00596414 -
Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial
|
Phase 4 | |
Active, not recruiting |
NCT02772003 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
Terminated |
NCT04775797 -
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
|
Phase 1 | |
Terminated |
NCT03487848 -
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
|
Phase 2 | |
Recruiting |
NCT02822079 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
Recruiting |
NCT04446832 -
VACcination of LIver Transplantation Candidates
|
||
Completed |
NCT01121705 -
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
|
Phase 3 | |
Completed |
NCT02742597 -
Patient-Centred Innovations for Persons With Multimorbidity - Ontario
|
N/A | |
Completed |
NCT05678582 -
Hepatic Steatosis and Chronic Hepatitis B Virus
|
||
Not yet recruiting |
NCT05062967 -
Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
|
||
Recruiting |
NCT01413360 -
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
|
Phase 4 | |
Terminated |
NCT00496002 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
Terminated |
NCT00496158 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
Completed |
NCT02789800 -
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
|
N/A |